Functional magnetic resonance imaging study of drug-resistant medial temporal lobe epilepsy
10.3760/cma.j.cn113694-20210512-00332
- VernacularTitle:耐药性内侧颞叶癫痫患者的功能影像磁共振研究
- Author:
Jingru HAO
1
;
Qiang XU
;
Qirui ZHANG
;
Fang YANG
;
Kangjian SUN
;
Guangming LU
;
Zhiqiang ZHANG
Author Information
1. 东部战区总医院（南京大学医学院附属金陵医院）放射诊断科，南京210002
- Keywords:
Epilepsy, temporal lobe;
Magnetic resonance imaging;
Corpus striatum;
Thalamus;
Functional connectivity density;
Drug-resistant
- From:
Chinese Journal of Neurology
2022;55(1):41-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the changes of brain activity in drug-resistant or drug-controlled medial temporal lobe epilepsy patients by the method of functional connectivity density (FCD), and to analyze their correlation with the course of the disease.Methods:According to the definition of drug-resistant epilepsy by the International League Against Epilepsy in 2010, 146 patients with medial temporal lobe epilepsy who were clearly diagnosed as unilateral hippocampal sclerosis in Jinling Hospital, Nanjing University School of Medicine from July 2009 to February 2019 were divided into drug control group ( n=73) and drug-resistant group ( n=73). The 3.0 T resting state functional magnetic resonance scan was performed on all subjects to compare the difference in FCD between the two groups, and calculate the correlation between the FCD value of the brain area and the course of the disease between the two groups of patients. Results:There was significant difference between the two groups in FCD. Compared with the drug control group, the drug-resistant group had significantly lower FCD values in the insula, lenticular nucleus, thalamus, hippocampus and precentral gyrus on the side of the epileptogenic focus. The FCD value of the precuneus on the side of the epileptogenic focus in the drug-resistant group was negatively correlated with the duration ( r=-0.30, P=0.01). Conclusions:The FCD of patients with drug-resistant medial temporal lobe epilepsy was lower than that of the drug control group. In addition, there may be progressive damage to the brain. The difference is helpful for exploring the pathophysiological mechanisms related to drug resistance in patients with medial temporal lobe epilepsy, and finding reliable neuroimaging markers related to drug resistance.
